

Based on preclinical models, it has been proposed that anti-VEGF agents exert continuous antivascular effects throughout tumor development. One of the most rapid of these proposed effects is regression of existing tumor vessels. Direct and rapid changes observed with anti-VEGF agents include a significant reduction in microvascular density.7,10-13 In addition to these more rapid effects, anti-VEGF agents may also result in ongoing inhibition of both new and recurrent tumor vessel growth.8,9,12 It has been proposed that these effects inhibit tumor growth and metastasis and improve the tumor vasculature's capacity for effective delivery of antitumor compounds.13-16